Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC-MPS vs MMF in de Novo Heart Transplant Recipients
NCT00574743Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2002
- Primary completion
- Apr 2004
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, randomised, single-blind trial of mycophenolate sodium in heart transplant rejection (2 arms), sponsored by Novartis. Primary endpoint: Incidence of biopsy-proven and treated acute rejection, graft loss or death at 6 months. Started Jan 2002; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
heart transplant rejection
Beyond the preview
Go deeper on NCT00574743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00574743.